Asset Details
Do you wish to reserve the book?
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Do you wish to request the book?
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
2017
Overview
In a trial involving patients with later-stage ADPKD, the V
2
-receptor antagonist tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period, which may slow the onset of end-stage kidney disease.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Age
/ Aged
/ Alanine
/ Alanine Transaminase - blood
/ Antidiuretic Hormone Receptor Antagonists - adverse effects
/ Antidiuretic Hormone Receptor Antagonists - therapeutic use
/ Benzazepines - adverse effects
/ Benzazepines - therapeutic use
/ Cysts
/ Female
/ Glomerular Filtration Rate - drug effects
/ Humans
/ Kidney Failure, Chronic - prevention & control
/ Male
/ Patients
/ Polycystic Kidney, Autosomal Dominant - blood
/ Polycystic Kidney, Autosomal Dominant - drug therapy
